A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV‐positive patients
Background Atazanavir (ATV), an HIV protease inhibitor (PI) that may be preferred for the treatment of HIV‐infected patients with cardiovascular comorbidities because of its favourable effects on plasma lipids, has been associated with cardiac rhythm disturbances. Objective To quantify the effect of...
Gespeichert in:
| Veröffentlicht in: | HIV medicine 2006-07, Vol.7 (5), p.317-322 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 322 |
|---|---|
| container_issue | 5 |
| container_start_page | 317 |
| container_title | HIV medicine |
| container_volume | 7 |
| creator | Busti, AJ Tsikouris, JP Peeters, MJ Das, SR Canham, RM Abdullah, SM Margolis, DM |
| description | Background
Atazanavir (ATV), an HIV protease inhibitor (PI) that may be preferred for the treatment of HIV‐infected patients with cardiovascular comorbidities because of its favourable effects on plasma lipids, has been associated with cardiac rhythm disturbances.
Objective
To quantify the effect of ATV on corrected QT (QTc) and QTc dispersion (QTd), markers of the potential for cardiac dysrhythmia, in patients switching from other PIs to ATV.
Methods
In this prospective, single‐centre, open‐label study, 12‐lead electrocardiograms were performed for subjects at baseline, 2 h after the first dose of ATV, and 1 month after initiation of ATV.
Results
Twenty‐one patients (19 received ritonavir‐boosted ATV) completed the study. There was a trend towards an increase in the QTc at 2 h after the first dose [mean±standard deviation 3.19±8.0 ms; 95% confidence interval (CI) −0.47 to 6.85 ms; P=0.084]. There was no difference between QTc values at baseline and at 1 month (−1.5±8.75 ms; 95% CI −5.50 to 2.46; P=0.43). There was a nonsignificant decrease in the QTd between baseline and 2 h (−5.1±15.19 ms; 95% CI −13.22 to 2.96; P=0.197) and between baseline and 1 month (−0.61±15.04 ms; 95% CI −8.1 to 6.87; P=0.865). A significant increase in the PR interval (7.4±10.7 ms; 95% CI 2.5 to 12.25 ms; P=0.005) was observed at 1 month.
Conclusions
The use of ATV did not result in increases in the QTc interval or QTd. However, PR interval monitoring may be warranted in patients with underlying heart block or those treated with atrioventricular nodal blocking agents. |
| doi_str_mv | 10.1111/j.1468-1293.2006.00382.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68805706</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17205381</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4472-57d64f98d62833b1a4554b05b698da7b2750c6867fe1b4c59c2499039be81bb63</originalsourceid><addsrcrecordid>eNqNUUtOwzAQtRCI_xWQV-wS_LcjsakQUCQkhFTYWnbiCFdpEuK0tKw4AmfkJDhtBUvwxjPzPpbnAQAxSnE8F9MUM6ESTDKaEoREihBVJF3ugMMfYHdds4QIQQ7AUQhThLCkGdoHB1hkjCMpD8FiBNuuCa3Le79w0C1MNTe9b2rYlLB_iZOyjNjQmd68m9osfAcjPGCPkxz6unddVEFTF-tB4aNbFwYLX8Px3fPXx2fbBL_2b6O3q_twAvZKUwV3ur2PwdPN9eRqnNw_3N5dje6TnDFJEi4LwcpMFYIoSi02jHNmEbcizoy0RHKUCyVk6bBlOc9ywrIM0cw6ha0V9Bicb3zjJ1_nLvR65kPuqsrUrpkHLZRCXKK_iVgSxKnCkag2xDyuLXSu1G3nZ6ZbaYz0EI6e6iEDPWSgh3D0Ohy9jNKz7RtzO3PFr3CbRiRcbghvvnKrfxvruORY0G9V655R</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17205381</pqid></control><display><type>article</type><title>A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV‐positive patients</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Free Content</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Busti, AJ ; Tsikouris, JP ; Peeters, MJ ; Das, SR ; Canham, RM ; Abdullah, SM ; Margolis, DM</creator><creatorcontrib>Busti, AJ ; Tsikouris, JP ; Peeters, MJ ; Das, SR ; Canham, RM ; Abdullah, SM ; Margolis, DM</creatorcontrib><description>Background
Atazanavir (ATV), an HIV protease inhibitor (PI) that may be preferred for the treatment of HIV‐infected patients with cardiovascular comorbidities because of its favourable effects on plasma lipids, has been associated with cardiac rhythm disturbances.
Objective
To quantify the effect of ATV on corrected QT (QTc) and QTc dispersion (QTd), markers of the potential for cardiac dysrhythmia, in patients switching from other PIs to ATV.
Methods
In this prospective, single‐centre, open‐label study, 12‐lead electrocardiograms were performed for subjects at baseline, 2 h after the first dose of ATV, and 1 month after initiation of ATV.
Results
Twenty‐one patients (19 received ritonavir‐boosted ATV) completed the study. There was a trend towards an increase in the QTc at 2 h after the first dose [mean±standard deviation 3.19±8.0 ms; 95% confidence interval (CI) −0.47 to 6.85 ms; P=0.084]. There was no difference between QTc values at baseline and at 1 month (−1.5±8.75 ms; 95% CI −5.50 to 2.46; P=0.43). There was a nonsignificant decrease in the QTd between baseline and 2 h (−5.1±15.19 ms; 95% CI −13.22 to 2.96; P=0.197) and between baseline and 1 month (−0.61±15.04 ms; 95% CI −8.1 to 6.87; P=0.865). A significant increase in the PR interval (7.4±10.7 ms; 95% CI 2.5 to 12.25 ms; P=0.005) was observed at 1 month.
Conclusions
The use of ATV did not result in increases in the QTc interval or QTd. However, PR interval monitoring may be warranted in patients with underlying heart block or those treated with atrioventricular nodal blocking agents.</description><identifier>ISSN: 1464-2662</identifier><identifier>EISSN: 1468-1293</identifier><identifier>DOI: 10.1111/j.1468-1293.2006.00382.x</identifier><identifier>PMID: 16945077</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Antiretroviral Therapy, Highly Active ; Arrhythmias, Cardiac - prevention & control ; Atazanavir Sulfate ; ATV ; electrocardiogram ; Electrocardiography - drug effects ; Female ; Heart Conduction System - drug effects ; Heart Rate - drug effects ; HIV Infections - drug therapy ; HIV Protease Inhibitors - pharmacology ; HIV Protease Inhibitors - therapeutic use ; Human immunodeficiency virus ; Humans ; Male ; Middle Aged ; Oligopeptides - pharmacology ; Oligopeptides - therapeutic use ; Prospective Studies ; Pyridines - pharmacology ; Pyridines - therapeutic use ; QT dispersion ; QT interval ; Treatment Outcome</subject><ispartof>HIV medicine, 2006-07, Vol.7 (5), p.317-322</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4472-57d64f98d62833b1a4554b05b698da7b2750c6867fe1b4c59c2499039be81bb63</citedby><cites>FETCH-LOGICAL-c4472-57d64f98d62833b1a4554b05b698da7b2750c6867fe1b4c59c2499039be81bb63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1468-1293.2006.00382.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1468-1293.2006.00382.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27903,27904,45553,45554,46387,46811</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16945077$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Busti, AJ</creatorcontrib><creatorcontrib>Tsikouris, JP</creatorcontrib><creatorcontrib>Peeters, MJ</creatorcontrib><creatorcontrib>Das, SR</creatorcontrib><creatorcontrib>Canham, RM</creatorcontrib><creatorcontrib>Abdullah, SM</creatorcontrib><creatorcontrib>Margolis, DM</creatorcontrib><title>A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV‐positive patients</title><title>HIV medicine</title><addtitle>HIV Med</addtitle><description>Background
Atazanavir (ATV), an HIV protease inhibitor (PI) that may be preferred for the treatment of HIV‐infected patients with cardiovascular comorbidities because of its favourable effects on plasma lipids, has been associated with cardiac rhythm disturbances.
Objective
To quantify the effect of ATV on corrected QT (QTc) and QTc dispersion (QTd), markers of the potential for cardiac dysrhythmia, in patients switching from other PIs to ATV.
Methods
In this prospective, single‐centre, open‐label study, 12‐lead electrocardiograms were performed for subjects at baseline, 2 h after the first dose of ATV, and 1 month after initiation of ATV.
Results
Twenty‐one patients (19 received ritonavir‐boosted ATV) completed the study. There was a trend towards an increase in the QTc at 2 h after the first dose [mean±standard deviation 3.19±8.0 ms; 95% confidence interval (CI) −0.47 to 6.85 ms; P=0.084]. There was no difference between QTc values at baseline and at 1 month (−1.5±8.75 ms; 95% CI −5.50 to 2.46; P=0.43). There was a nonsignificant decrease in the QTd between baseline and 2 h (−5.1±15.19 ms; 95% CI −13.22 to 2.96; P=0.197) and between baseline and 1 month (−0.61±15.04 ms; 95% CI −8.1 to 6.87; P=0.865). A significant increase in the PR interval (7.4±10.7 ms; 95% CI 2.5 to 12.25 ms; P=0.005) was observed at 1 month.
Conclusions
The use of ATV did not result in increases in the QTc interval or QTd. However, PR interval monitoring may be warranted in patients with underlying heart block or those treated with atrioventricular nodal blocking agents.</description><subject>Antiretroviral Therapy, Highly Active</subject><subject>Arrhythmias, Cardiac - prevention & control</subject><subject>Atazanavir Sulfate</subject><subject>ATV</subject><subject>electrocardiogram</subject><subject>Electrocardiography - drug effects</subject><subject>Female</subject><subject>Heart Conduction System - drug effects</subject><subject>Heart Rate - drug effects</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Protease Inhibitors - pharmacology</subject><subject>HIV Protease Inhibitors - therapeutic use</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Oligopeptides - pharmacology</subject><subject>Oligopeptides - therapeutic use</subject><subject>Prospective Studies</subject><subject>Pyridines - pharmacology</subject><subject>Pyridines - therapeutic use</subject><subject>QT dispersion</subject><subject>QT interval</subject><subject>Treatment Outcome</subject><issn>1464-2662</issn><issn>1468-1293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUUtOwzAQtRCI_xWQV-wS_LcjsakQUCQkhFTYWnbiCFdpEuK0tKw4AmfkJDhtBUvwxjPzPpbnAQAxSnE8F9MUM6ESTDKaEoREihBVJF3ugMMfYHdds4QIQQ7AUQhThLCkGdoHB1hkjCMpD8FiBNuuCa3Le79w0C1MNTe9b2rYlLB_iZOyjNjQmd68m9osfAcjPGCPkxz6unddVEFTF-tB4aNbFwYLX8Px3fPXx2fbBL_2b6O3q_twAvZKUwV3ur2PwdPN9eRqnNw_3N5dje6TnDFJEi4LwcpMFYIoSi02jHNmEbcizoy0RHKUCyVk6bBlOc9ywrIM0cw6ha0V9Bicb3zjJ1_nLvR65kPuqsrUrpkHLZRCXKK_iVgSxKnCkag2xDyuLXSu1G3nZ6ZbaYz0EI6e6iEDPWSgh3D0Ohy9jNKz7RtzO3PFr3CbRiRcbghvvnKrfxvruORY0G9V655R</recordid><startdate>200607</startdate><enddate>200607</enddate><creator>Busti, AJ</creator><creator>Tsikouris, JP</creator><creator>Peeters, MJ</creator><creator>Das, SR</creator><creator>Canham, RM</creator><creator>Abdullah, SM</creator><creator>Margolis, DM</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200607</creationdate><title>A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV‐positive patients</title><author>Busti, AJ ; Tsikouris, JP ; Peeters, MJ ; Das, SR ; Canham, RM ; Abdullah, SM ; Margolis, DM</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4472-57d64f98d62833b1a4554b05b698da7b2750c6867fe1b4c59c2499039be81bb63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Antiretroviral Therapy, Highly Active</topic><topic>Arrhythmias, Cardiac - prevention & control</topic><topic>Atazanavir Sulfate</topic><topic>ATV</topic><topic>electrocardiogram</topic><topic>Electrocardiography - drug effects</topic><topic>Female</topic><topic>Heart Conduction System - drug effects</topic><topic>Heart Rate - drug effects</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Protease Inhibitors - pharmacology</topic><topic>HIV Protease Inhibitors - therapeutic use</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Oligopeptides - pharmacology</topic><topic>Oligopeptides - therapeutic use</topic><topic>Prospective Studies</topic><topic>Pyridines - pharmacology</topic><topic>Pyridines - therapeutic use</topic><topic>QT dispersion</topic><topic>QT interval</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Busti, AJ</creatorcontrib><creatorcontrib>Tsikouris, JP</creatorcontrib><creatorcontrib>Peeters, MJ</creatorcontrib><creatorcontrib>Das, SR</creatorcontrib><creatorcontrib>Canham, RM</creatorcontrib><creatorcontrib>Abdullah, SM</creatorcontrib><creatorcontrib>Margolis, DM</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>HIV medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Busti, AJ</au><au>Tsikouris, JP</au><au>Peeters, MJ</au><au>Das, SR</au><au>Canham, RM</au><au>Abdullah, SM</au><au>Margolis, DM</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV‐positive patients</atitle><jtitle>HIV medicine</jtitle><addtitle>HIV Med</addtitle><date>2006-07</date><risdate>2006</risdate><volume>7</volume><issue>5</issue><spage>317</spage><epage>322</epage><pages>317-322</pages><issn>1464-2662</issn><eissn>1468-1293</eissn><abstract>Background
Atazanavir (ATV), an HIV protease inhibitor (PI) that may be preferred for the treatment of HIV‐infected patients with cardiovascular comorbidities because of its favourable effects on plasma lipids, has been associated with cardiac rhythm disturbances.
Objective
To quantify the effect of ATV on corrected QT (QTc) and QTc dispersion (QTd), markers of the potential for cardiac dysrhythmia, in patients switching from other PIs to ATV.
Methods
In this prospective, single‐centre, open‐label study, 12‐lead electrocardiograms were performed for subjects at baseline, 2 h after the first dose of ATV, and 1 month after initiation of ATV.
Results
Twenty‐one patients (19 received ritonavir‐boosted ATV) completed the study. There was a trend towards an increase in the QTc at 2 h after the first dose [mean±standard deviation 3.19±8.0 ms; 95% confidence interval (CI) −0.47 to 6.85 ms; P=0.084]. There was no difference between QTc values at baseline and at 1 month (−1.5±8.75 ms; 95% CI −5.50 to 2.46; P=0.43). There was a nonsignificant decrease in the QTd between baseline and 2 h (−5.1±15.19 ms; 95% CI −13.22 to 2.96; P=0.197) and between baseline and 1 month (−0.61±15.04 ms; 95% CI −8.1 to 6.87; P=0.865). A significant increase in the PR interval (7.4±10.7 ms; 95% CI 2.5 to 12.25 ms; P=0.005) was observed at 1 month.
Conclusions
The use of ATV did not result in increases in the QTc interval or QTd. However, PR interval monitoring may be warranted in patients with underlying heart block or those treated with atrioventricular nodal blocking agents.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>16945077</pmid><doi>10.1111/j.1468-1293.2006.00382.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-2662 |
| ispartof | HIV medicine, 2006-07, Vol.7 (5), p.317-322 |
| issn | 1464-2662 1468-1293 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68805706 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Free Content; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Antiretroviral Therapy, Highly Active Arrhythmias, Cardiac - prevention & control Atazanavir Sulfate ATV electrocardiogram Electrocardiography - drug effects Female Heart Conduction System - drug effects Heart Rate - drug effects HIV Infections - drug therapy HIV Protease Inhibitors - pharmacology HIV Protease Inhibitors - therapeutic use Human immunodeficiency virus Humans Male Middle Aged Oligopeptides - pharmacology Oligopeptides - therapeutic use Prospective Studies Pyridines - pharmacology Pyridines - therapeutic use QT dispersion QT interval Treatment Outcome |
| title | A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV‐positive patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T16%3A22%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20prospective%20evaluation%20of%20the%20effect%20of%20atazanavir%20on%20the%20QTc%20interval%20and%20QTc%20dispersion%20in%20HIV%E2%80%90positive%20patients&rft.jtitle=HIV%20medicine&rft.au=Busti,%20AJ&rft.date=2006-07&rft.volume=7&rft.issue=5&rft.spage=317&rft.epage=322&rft.pages=317-322&rft.issn=1464-2662&rft.eissn=1468-1293&rft_id=info:doi/10.1111/j.1468-1293.2006.00382.x&rft_dat=%3Cproquest_cross%3E17205381%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17205381&rft_id=info:pmid/16945077&rfr_iscdi=true |